Literature DB >> 17022969

Involvement of 5-hydroxytryptamine1A receptors in Delta9-tetrahydrocannabinol-induced catalepsy-like immobilization in mice.

Nobuaki Egashira1, Tomomi Matsuda, Emi Koushi, Kenichi Mishima, Katsunori Iwasaki, Yukihiro Shoyama, Michihiro Fujiwara.   

Abstract

The present study investigated the involvement of 5-hydroxytryptamine(1A) (5-HT(1A)) receptors in Delta(9)-tetrahydrocannabinol (THC)-induced catalepsy-like immobilization in mice. THC (10 mg/kg, i.p.) induced catalepsy-like immobilization but had no effect on motor coordination in the rota-rod test. The selective cannabinoid CB(1) receptor antagonist rimonabant (3 mg/kg, i.p.) completely antagonized THC-induced catalepsy-like immobilization. The 5-HT(1A)/5-HT(7) receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT; 0.3 and 1 mg/kg, i.p.) and 5-HT(1A) receptor partial agonist buspirone (0.06 and 0.1 mg/kg, i.p.) inhibited this THC-induced catalepsy-like immobilization. Moreover, the selective 5-HT(1A) receptor antagonist N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl) cyclohezane carboxamide dihydrochloride (WAY100635; 0.3 or 1 mg/kg, i.p.) reversed the inhibition of THC-induced catalepsy-like immobilization by 8-OH-DPAT (1 mg/kg) or buspirone (0.06 mg/kg). In contrast, the selective 5-HT(7) receptor antagonist (R)-3-[2-[2-(4-methylpiperidin-1-yl)ethyl]pyrrolidine-1-sulfonyl]phenol hydrochloride (SB269970) had no effect on this inhibitory effect of 8-OH-DPAT. On the other hand, WAY100635 (0.3 and 1 mg/kg, i.p.) enhanced the catalepsy-like immobilization induced by THC (6 mg/kg, i.p.). These findings suggest that the 5-HT(1A) receptors are involved in THC-induced catalepsy-like immobilization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17022969     DOI: 10.1016/j.ejphar.2006.08.051

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

Review 1.  Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users?

Authors:  Patrycja Kleczkowska; Irena Smaga; Małgorzata Filip; Magdalena Bujalska-Zadrozny
Journal:  Neurotox Res       Date:  2016-08-02       Impact factor: 3.911

2.  The effect of chronic administration of buspirone on 6-hydroxydopamine-induced catalepsy in rats.

Authors:  Hamdolah Sharifi; Alireza Mohajjel Nayebia; Safar Farajnia
Journal:  Adv Pharm Bull       Date:  2012-05-15

3.  Role of vasopressin V1a receptor in ∆9-tetrahydrocannabinol-induced cataleptic immobilization in mice.

Authors:  Nobuaki Egashira; Emi Koushi; Takayuki Myose; Akito Tanoue; Kenichi Mishima; Ryota Tsuchihashi; Junei Kinjo; Hiroyuki Tanaka; Satoshi Morimoto; Katsunori Iwasaki
Journal:  Psychopharmacology (Berl)       Date:  2017-09-14       Impact factor: 4.530

4.  Chronic treatment and withdrawal of the cannabinoid agonist WIN 55,212-2 modulate the sensitivity of presynaptic receptors involved in the regulation of monoamine syntheses in rat brain.

Authors:  David Moranta; Susana Esteban; Jesús A García-Sevilla
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-08-16       Impact factor: 3.000

5.  Effect of the CB(1) receptor antagonists rimonabant and AM251 on the firing rate of dorsal raphe nucleus neurons in rat brain slices.

Authors:  Aitziber Mendiguren; Joseba Pineda
Journal:  Br J Pharmacol       Date:  2009-10-20       Impact factor: 8.739

Review 6.  Emerging strategies for exploiting cannabinoid receptor agonists as medicines.

Authors:  Roger G Pertwee
Journal:  Br J Pharmacol       Date:  2009-02       Impact factor: 8.739

Review 7.  Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke.

Authors:  Kazuhide Hayakawa; Kenichi Mishima; Michihiro Fujiwara
Journal:  Pharmaceuticals (Basel)       Date:  2010-07-08

8.  Genetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice.

Authors:  Krisztina Monory; Heike Blaudzun; Federico Massa; Nadine Kaiser; Thomas Lemberger; Günther Schütz; Carsten T Wotjak; Beat Lutz; Giovanni Marsicano
Journal:  PLoS Biol       Date:  2007-10       Impact factor: 8.029

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.